Navigation Links
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Date:8/19/2007

esponse(TM) DNA platform can overcome the time, capacity

and cost challenges of manufacturing conventional vaccines for diseases

such as influenza, which use killed or disabled viruses grown in

chicken eggs or via cell culture, requiring months of production time

in large, dedicated facilities.

Conference Call

Vical will conduct a conference call and webcast to discuss the financial results and program updates with invited analysts and institutional investors today, August 7, at noon Eastern Time. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial (888) 224-3260, or (913) 905-1086 for international participants, and reference confirmation code 3989047. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 3989047. The call also will be available live and archived through the events page at http://www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical compa
'/>"/>

SOURCE Vical

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... the prior year. Reported sales increased 5% which included ... per diluted share as reported (EPS) were $2.49, compared ... EPS was $2.57, an increase of 9% over the ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
(Date:7/24/2014)... , July 24, 2014 IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... Board of Directors.  Mr. Finio has accepted a senior ... the terms of his acceptance of his new position, ... role as Director for IGI Laboratories, Inc.  The effective ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... BEIJING, May 7, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in the People,s Republic of China, ... covering its first quarter 2012 results on May 9, 2012 ... p.m. in China on the same day. Hosting ...
... S. Weinstock and G. Scott Vezina of ... obtained a $78.5 million verdict on behalf of a child ... negligence. The child, now 3 years old, has severe spastic ... of an emergency cesarean section delivery. The case was tried, ...
Cached Medicine Technology:China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY) 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 3
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
(Date:7/25/2014)... Texas (PRWEB) July 26, 2014 ... and China Gel Permeation Chromatography Industryā€¯ is ... the Global and China Gel Permeation Chromatography ... Chromatography information, including Gel Permeation Chromatography definition, ... well as industry overview. This research covers ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... 2014 American motor vehicle owners who ... can pay higher premiums for vehicle insurance on average. ... network to provide SR22 insurance for high risk motorists ... different coverage network of local agencies providing direct price ... platform now publicly available for any car owner to ...
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
Breaking Medicine News(10 mins):Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Multiple States Crack Down on Heroin Epidemic 2
... to patients with a history of growths in their colon ... believe that most colorectal cancer develop out of polyps, or ... ,However, the latest research, conducted in France, Denmark, Italy ... to grow in patients given this fibre supplementation. In 456 ...
... researchers, a new treatment has been effective for inoperable liver cancer. It ... and it is showing a 25 ... per cent success rate in either reducing tumour size or the ... treatment with advanced liver tumours, who cannot be treated by any other ...
... people who suffer from dementia benefit from music therapy. The ... music. The trials have found that the therapy is popular ... ,scientists at Imperial College London are planning to carry out ... therapy has long term benefits for dementia sufferers. If their ...
... supplements given to babies with low birth weight can ... often die from infectious diseases. The research involved 1,154 ... Delhi, India, most weighing 5 1/2 pounds or less. ... nine months. Fifteen of the 20 who died had ...
... India (MSI), the sole franchisee for US based Medicine Shoppe ... has dropped Chennai from list of its target for operations ... drew up plans to expand its franchisee operations from the ... current financial year, has decided to put on hold the ...
... heavy breakfast and a steaming cup of tea may increase a ... fried food each morning are at twice the risk of the ... reduce the incidence of cancer is to begin the day with ... of the oesophagus - the food pipe connecting the stomach with ...
Cached Medicine News:Health News:Cut down on fries 2
... Solo microplate incubator is an extremely ... a single microplate up to 50C. ... applications requiring higher temperatures up to ... offering low cost and high performance ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Medicine Products: